Optimising 18F-Choline PET/CT acquisition protocol in prostate cancer patients

North American Journal of Medical Sciences

Volumn 4, Issue 9, 2012, Pages 416-420

  Massaro, Arianna ^a   Ferretti, Alice ^a   Secchiero, Chiara ^a   Cittadin, Silvia ^a   Milan, Elisa ^a   Tamiso, Luca ^a   Pavan, Lara ^a   Tommasi, Enrico ^a   Marzola, Maria Cristina ^a   Chondrogiannis, Sotirios ^a   Rampin, Lucia ^a   Marcolongo, Adriano ^a   Rubello, Domenico ^a  

^a Santa Maria della Misericordia Hospital   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINE; FLUORINE 18; IASOCHOLINE; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; CANCER RELAPSE; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC PROCEDURE; DOSIMETRY; HISTOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; LETTER; MALE; PROSTATE CANCER; PROSTATECTOMY; WHOLE BODY CT; WHOLE BODY PET;

EID: 84866464869     PISSN: 22501541     EISSN: 19472714     Source Type: Journal    
DOI: 10.4103/1947-2714.100994     Document Type: Letter

References (19)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Ferlay J, Siegel R, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008 Cancer incidence and mortality worldwide: IARC cancerbase No.10. Lyon: International Agency for Research on Cancer; 2010. Available from: http://globocan.iarc.fr/. [Last accessed on 2011 Nov 25].
3. 11C-Choline. J Nucl Med 2011;52:81-9.
4. 11C]Choline PET/CT imaging in occult local relapse of prostate cancer after radical prostatectomy. Eur J Nucl Med Mol Imaging 2008;35:9-17.
5. 11C-Choline PET/CT with histopathologic step- section analysis. J Nucl Med 2005;46:1642-9.
6. Castellucci P, Fuccio C, Marzola MC, Al-Nahhas A, Rubello D, Fanti S. Prostate-specific antigen kinetics and choline PET/CT in patients with biochemical relapse after primary treatment for prostate cancer. Nucl Med Commun 2011;32:475-8.
7. 18F-labeled choline as an oncologic tracer for positron emission tomography: Initial findings in prostate cancer. Cancer Res 2000;61:110-7.
8. 18F]-choline PET/CT for staging and restaging of prostate cancer. Eur J Nucl Med Mol Imaging 2008;35:253-63.
9. Heinisch M, Dirisamer A, Loidl W, Stroiber F, Gruy B, Haim S, et al. Positron emission tomography/computed tomography with F-18-fluorocholine for restaging of prostate cancer patients: meaningful at PSA < 5 ng/ml? Mol Imaging Biol 2006;8:43-8.
10. 18F]Fluorocholine positron emission tomography- computerized tomography and laparoscopic radioisotope guided sentinel lymph node dissection. J Urol 2006;176:2014-9.
11. Stamm G, Nagel HD. CT-Expo- a novel program for dose evaluation in CT. Rofo 2002;74:1570-6.
12. DeGrado TR, Reiman RE, Price DT, Wang S, Coleman RE. Pharmacokinetics and radiation dosimetry of 18F-fluorocholine. J Nucl Med 2002;43:92-6.
13. Erratum in: DeGrado TR, Reiman RE, Price DT, Wang S, Coleman RE. J Nucl Med 2002;43:509.
14. ICRP. The 2007 Recommendations of the International Commission on Radiological Protection. Vol. 37. ICRP Publication 103. Ann. ICRP; 2008.
15. Freedland SJ, Presti JC, Amling CL, Kane CJ, Aronson WJ, Dorey F, et al. Time trends in biochemical recurrence after radical prostatectomy: Results of the search database. Urol 2003;61:736-41.
16. Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 2003;169:517-23.
17. Giovacchini G, Picchio M, Coradeschi E, Bettinardi V, Gianolli L, Scattoni V, et al. Predictive factors of [(11)C]choline PET/CT in patients with biochemical failure after radical prostatectomy. Eur J Nucl Med Mol Imaging 2010;37:301-9.
18. ICRP. Managing patient dose in Multi-Detector Computed Tomography (MDCT). Vol. 37. ICRP Publication 102. Ann. ICRP; 2007, Stockholm, Sweden.
19. Würschmidt F, Petersen C, Wahl A, Dahle J, Kretschmer M. [18F]fluoroethylcholine-PET/CT imaging for radiation treatment planning of recurrent and primary prostate cancer with dose escalation to PET/CT-positive lymph nodes. Radiat Oncol 2011;6:44.